News Sentiment

STOK sentiment intelligence

Stoke Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.38 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +5.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 5.2% over four weeks
Fair value 97.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 7
MarketBeat 6
TradingView 4
Business Wire 3
Simply Wall Street 3
simplywall.st 3
Biogen 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 20
Analyst action 5
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Simply Wall Street Direct company coverage

Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?

Stoke Therapeutics (STOK) was removed from several Russell indices, including the Russell Microcap and Russell 3000E, on June 27, 2026. This removal is expected to alter the company's investor base and trading patterns, potentially impacting its investment narrative and risk prof

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:10
Source
Simply Wall Street
MarketBeat Direct company coverage

Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK

Assenagon Asset Management S.A. reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 26.1% in the first quarter, selling 320,708 shares and retaining 907,015 shares valued at $29.5 million. Despite insider selling by General Counsel Jonathan Allan and insider Barry Ticho, ana

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:10
Source
MarketBeat
TradingView Direct company coverage

Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK

This article displays the "Price to sales forward" metric for Stoke Therapeutics, Inc. (NASDAQ: STOK) on the TradingView platform. It shows the current value, change, and percentage change for this financial indicator. The content is primarily a data display with minimal descript

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:10
Source
TradingView